NCT05611879View on ClinicalTrials.gov

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 12, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

April 30, 2024

Conditions
NSCLC, Stage III
Interventions
DRUG

Tislelizumab

Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles

DRUG

Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)

Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.

DRUG

Carboplatin

AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.

Trial Locations (1)

Unknown

RECRUITING

Beijing Tsinghua Chang Gung Hospital, Beijing

All Listed Sponsors
lead

Beijing Tsinghua Chang Gung Hospital

OTHER